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Abstract 
Avian influenza viruses (AIV), the causative agent of avian flu or bird flu, cause widespread 
morbidity and mortality in poultry. The symptoms of the disease range from mild flu like 
symptoms to death. These viruses possess two important surface glycoproteins, namely 
hemagglutinin (HA) and neuraminidase (NA) against which neutralizing antibodies are pro-
duced. Due to the highly mutative nature of the genes which encode these proteins, the vi-
ruses often confer resistance to the current anti-viral drugs making the prevention and 
treatment of infection challenging. In our laboratory, we have recently identified a novel 
anti-viral peptide (P1) against the AIV H9N2 from a phage displayed peptide library. This 
peptide inhibits the replication of the virus in ovo and in vitro by its binding to the HA glyco-
protein. In the current study, we demonstrate that the peptide inhibits the virus replication 
by preventing the attachment to the host cell but it does not have any effect on the viral fu-
sion. The reduction in the viral nucleoprotein (NP) expression inside the host cell has also 
been observed during the peptide (P1) treatment. This novel peptide may have the potential 
to be developed as a therapeutic agent for the treatment and control of avian influenza virus 
H9N2 infections. 
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1. Introduction 
Avian influenza virus belongs to the family of 
Orthomyxoviridae which comprises three genera in-
fluenza A, B and C. The influenza A virus has been 
divided into several subtypes based on the variation 
in the HA and NA glycoproteins. There are currently 
16 HA and 9 NA subtypes circulating among wild 
birds (1). Although these viruses are present in the 
wild birds they usually do not cause any disease 
among them but the poultry birds are severely af-
fected by highly pathogenic form of AIVs (1). Other 
than culling the birds (2) there are currently two 
classes of anti-viral drugs being administered for the 
control and treatment of AIV infection. They are 
adamantane derivatives (amantadine and riman-
tadine) and neuraminidase inhibitors (NAI; zanamivir 
and oseltamivir) (3-5). The increasing rate in the 
emergence of adamantane and NAI resistant strains 
stresses the need to develop new class of anti-viral 
drugs (4, 6-11).  




peptide based anti-viral molecule against the AIV 
H9N2 (12). The peptide was protective against the 
virus replication in ovo and in vitro and inhibited the 
hemagglutination activity of the virus. The peptide’s 
ability to compete with the anti-AIV antibodies 
proved that they share some common binding sites. 
From yeast two-hybrid and co-immunoprecipitation 
experiments, it has been observed that the peptide 
binds with the HA protein of the virus (12) suggesting 
that the peptide could either be involved during the 
attachment of the virus to the host cell receptors or in 
the fusion of the virus into the infected cells (13).  
In an effort to understand the mechanism of ac-
tion by the P1 peptide during virus replication, we 
demonstrate here that the P1 inhibits the latter by 
preventing its attachment to the host cell. We also 
show that it does not have any effect on the fusion 
ability of virus. 
2. Materials and Methods 
2.1 Virus Propagation and Purification 
Avian influenza A/Chicken/Iran/16/2000(H9N 
2), a low pathogenic avian influenza virus was kindly 
provided by Abdul Rahman Omar. Viruses were 
propagated in 9-days old specific pathogen free em-
bryonated chicken eggs. The allantoic fluid was clari-
fied and the viruses were purified and concentrated as 
explained previously (14). The virus titer was deter-
mined by hemagglutination test (HA) and the protein 
concentration of the purified virus was determined by 
Bradford assay (15). 
2.2 Fluorescent labeling of the virus 
The sucrose gradient purified viruses were la-
belled with FITC using the FITC labelling kit (Pierce, 
USA) as per the instructions given by the manufac-
turer. The infectious ability of the FITC labelled vi-
ruses was confirmed by observing the formation of 
cytopathic effects (CPE) in MDCK cells. 
2.3 Peptides 
Peptides were synthesised at GL Biochem, 
Shanghai, China with more than 98% purity. The 
peptides contained the sequences as mentioned in 
Table 1. 
Table 1: Peptides used in this study 
Name of the peptide  Sequence of the peptide 
P1 CNDFRSKTC 
Control Peptide  CSWGEYDMC 
 
2.4 Immunofluorescence assay 
  M D C K  c e l l s  w e r e  s e e d e d  o n  g l a s s  c o v e r s l i p s  
(Secureslip™, Sigma, USA) at a density of 5 x 104, were 
inoculated with medium alone, virus (moi of 0.5) or 
peptide-treated (0 to 100 µM) virus for 1 h on ice. The 
unbound viruses were removed by washing with 
magnesium and calcium free cold PBS. For en-
try-based assays, untreated virus was allowed to at-
tach on ice for 1 h, followed by washing and addition 
o f  m e d i u m  c o n t a i n i n g  p e p t i d e  ( 0  t o  5 0  µ M ) .  C e l l s  
were shifted to 37°C for 6 h, fixed with ice cold 
methanol and permeabilised with acetone. They were 
stained for nucleoprotein with mouse monoclonal 
anti-nucleoprotein antibodies (AA5H, 1:100; Abcam, 
USA) for 1 h and FITC-labelled goat polyclonal sec-
ondary antibody (1:200; Abcam, USA) diluted in PBS 
containing 0.1 % Tween-20 and 1 % BSA for 1 h at 
room temperature. The coverslip was air dried and 
mounted in ProLong Gold (Molecular Probes, USA), 
and fluorescence was examined on a microscope 
(Leica Microsystem, Wetzlar, Germany) at a total 
magnification of x100. Three randomly selected fields 
in each experimental group were counted for nucleo-
protein positive cells within this group. Data pre-
sented are the mean of at least three independent ex-
periments. 
2.5 Flow cytometry 
 MDCK suspension cells (1 x 106) were infected 
with FITC-labelled peptide treated (0 to 50 µM) or 
untreated AIV H9N2 virus (16 HA units) for 1 h on 
ice. After rigorous washing with PBS, the cells were 
fixed with 1 % paraformaldehyde, and the binding 
was determined by flow cytometric analysis (Cyan 
ADP, Dako, Denmark) after 24 hrs. Forward and side 
scatter characteristics were analysed for 5000 events of 
mock-infected or infected cells. 
2.6 Statistical analysis 
  All experiments were carried out in triplicate 
and are representative of at least three separate ex-
periments unless otherwise mentioned. The results 
represent the means ± standard deviations of tripli-
cate determinations. Statistical significance of the data 
was determined by student’s t t e s t  o r  A N O V A  
method using SPSS 13.0 software. A P value of < 0.05 
was considered statistically significant. 
3. Results and Discussion 
3.1 Effect of inhibitory peptide on viral attachment 
 To evaluate the effect of the anti-viral peptide on 
viral attachment, a flow cytometry based experiment 
was used. Briefly, MDCK suspension cells were in-
cubated with FITC-labelled, peptide P1 treated (0 to 
50 µM) or untreated AIV H9N2 virus for 1 h on ice. 
The fluorescence of virus infected cells was reduced 




a dose dependent manner. At 50 µM concentration of 
the peptide treatment, the fluorescence was reduced 
significantly (p < 0.05) i.e., more than 50 % (Table 2). 
The control peptide did not show any significant re-
duction (P > 0.05) in the fluorescence (Table 2). This 
result suggests that the peptide prevents the attach-
ment of the virus to the host cell receptor. This result 
is in consistent with our earlier observation of inhibi-
tion of hemagglutination activity of the virus (12) and 
again ensures that the peptide act by binding with the 
HA protein of the virus. 
 
Table 2: Effect of the peptides on viral attachment to host 
cells 
Peptide (P1) Concentration  % Fluorescence after treatment ^
0 µM  100 
10 µM  70.08 ± 1.94 * 
20 µM  62.12 ± 2.48 * 
50 µM  47.58 ± 1.27 * 
Control peptide 50 μM  98.3 ± 1.04 
^ The results are mean ± standard deviation of three separate ex-
periments. All the values in the above table were normalized to 0 
μM treatment which was considered to possess 100 % fluorescence. 
*, Statistical significance (P < 0.05)  
 
3.2 Effect of inhibitory peptides on viral 
entry 
  To investigate the effects of pep-
tide on viral entry into the host cells, a 
fluorescence microscopy based experi-
ment was performed based on the hy-
pothesis that the early protein expres-
sion will be inhibited if the virus entry is 
prevented. Briefly, MDCK cells were 
incubated with medium alone or in-
fected with the H9N2 virus at 4°C to 
allow virus attachment to the cells. After 
one hour incubation period, the cells were incubated 
with various concentration of (0 to 50 µM) cyclic pep-
tide for 15 min at 4°C. This was followed by incuba-
tion at 37°C for 6 h as the entry requires higher tem-
perature (37°C) (16-18). Later, the cells were stained 
for viral nucleoprotein (NP) to detect the presence of 
viral particles inside the cell. Three randomly selected 
fields in each experimental group were counted for 
nucleoprotein positive cells within this group. The NP 
protein expression pattern was similar in all cases. 
Both the anti-viral peptide ‘P1’ and control peptide do 
not reduce the NP protein expression significantly (P 
> 0.05) even at higher concentration (50 µM). The 
fluorescence stained NP protein expression was 
around 20 % in all concentrations of peptide treatment 
(Figure 1). Together with the flow cytometry based 
experiment explained above, this implies that the 
peptide does not affect the viral entry but affects only 
the viral attachment. Although the viral attachment 
and entry is controlled by the same HA protein of the 
virus, specific regions on the HA have been shown to 
be involved in either entry or attachment (16, 19). 
Therefore, it was possible that only regions which are 
not involved in entry are involved in the P1 interac-
tion with the host. 
 
 
Figure 1: Effect of the peptide P1 on viral 
entry. MDCK cells were infected with H9N2 
virus (moi of 0.5) for 1 h on ice. After the 
unbound viruses were removed by washing 
peptides were added for 15 min at 4°C; the 
temperature was shifted to 37°C for 6 hrs 
and NP expressed was determined. Frame 
(a) & (c) – Peptide P1; 30 & 50 µM respec-
tively, Frame (b) & (d) – Control peptide 
[CSWGEYDMC]; 30 & 50 µM respectively; 
Frame (e) No peptide treatment. The results 
represent the means of triplicate determi-
nations. 





3.3 Effect of inhibitory peptides on viral early protein ex-
pression 
  In order to examine whether the P1 peptide in-
hibited the early or late stage of viral replication, NP 
expression was monitored by immunofluorescence 
microscopy. NP is one of the immediate early proteins 
expressed during the AIV replication inside the host 
cell. Viruses were treated with various concentrations 
of P1 as well as control peptides (0 to 50 µM). MDCK 
cells were incubated with peptide treated or untreated 
virus H9N2 (moi of 0.5) for 1 h at 4°C to synchronize 
the infection. Unbound viruses were removed by rig-
orous washing with PBS. Then the temperature was 
shifted to 37°C for 6 hrs to allow the internalization of 
the virus inside the host cells. After fixation and per-
meabilization, the cells were stained for NP protein 
expression with fluorescent labelled antibodies as 
explained above and examined under immunofluo-
rescence microscope. Three different fields from each 
treatment and each containing 50 cells were counted 
to determine the percentage of NP positive cells. The 
level of NP expression was reduced with increasing 
concentration of peptide P1 treatment. More than 29 
% of control peptide treated or untreated (Figure 2; 
frame b and c) cells were NP positive when compared 
to mock infected cells (Figure 2; frame a). The NP ex-
pression was reduced at a dose dependent manner. At 
50 µM peptide treatment, the positive cells were 9 % 
(Figure 2; frame d) whereas at 100 µM peptide treat-
ment, it was further reduced to less than 2 % (Figure 2; 
frame e). It was a statistically significant reduction (p 
< 0.05). The observation shows that the peptide P1 
inhibits the early stage of the viral infection inde-
pendent of the prevention of virus entry. There was a 
small reduction in the early gene expression with 
control peptide treatment. This reduction is not sta-
tistically significant. Besides, this reduction was not 
dose dependant. 
 
Figure 2: Effect of anti-viral peptide on early gene expression. MDCK cells were incubated with medium alone (a), control 
peptide [CSWGEYDMC] (30 µM) treated (b) or peptide P1 treated [0 µM – (c); 50 µM – (d); 100 µM – (e)] viruses H9N2 
(moi of 0.5) for 1 h on ice. After shifting the temperature to 37°C, the NP protein expression was monitored by im-
munofluorescence microscopy. The results represent the means of triplicate determinations. *, Statistical significance (P < 





Viruses should penetrate the host cells in order 
to cause infection. Like most of the enveloped viruses, 
the influenza viruses use receptor binding and fusion 
as principal route of entry. The HA protein of the vi-
rus interacts with the host cell sialic acid receptors and 
enters by receptor-mediated endocytosis (20). There 
are two important binding regions in the HA protein 
of the influenza virus which are responsible for the 
attachment and entry of the virus to the host cell. The 
attachment region is present in the HA1 domain 
whereas the binding or fusion region is present in the 
HA2 domain of the protein and their functions are 
independent of each other (13). Although the virus 
can attach to the host cell receptors even at 4° C, the 
fusion protein requires 37° C for its activity (16, 21, 
22). Based on this fact, the study was designed to in-
vestigate whether the anti-viral peptides inhibited the 
attachment or the entry of virus to the cell. The ob-
servation showed us that the peptide inhibit the virus 
replication by blocking its attachment but not the en-
try.  
Prevention of viral entry is an attractive 
anti-viral strategy as it can minimize the chance of 
virus evolution and subsequent drug resistant strain 
development. It can inactivate the virus at an early 
stage and block the cell-cell spread (23). Besides, since 
the entry protein is present extracellularly, the drug 
molecules can reach the target easier than intracellular 
viral proteins.  
Once the virus enters the cell, the ribonucleo-
proteins are released into the cytoplasm and then 
transported to the nucleus. It is one of the early pro-
teins expressed upon the onset of viral infection (24). 
So, the investigation of the expression level of influ-
enza virus nucleoprotein (NP) is a good indicator to 
check the efficiency of the viral inhibitor. This ex-
periment shows that the entry inhibitor blocks the 
early viral replication independent of whether the 
virus fusion or entry is inhibited or not. 
4. Conclusion 
In conclusion, the novel peptide identified in our 
previous study inhibits the avian influenza virus rep-
lication by blocking its attachment to the host cell and 
thereby preventing the early viral genes expression. 
Given the importance to the public health problems 
caused by these viruses, the understanding of vi-
rus-cell interaction and the prevention of this early 
step of infection is necessary to combat the disease. 
We believe that the P1 peptide has the potential to 
study the host-pathogen interaction and also possess 
therapeutic qualities. 
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